Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ranbaxy's Loss Is Dr. Reddy's Gain As Merck Shifts R&D Project For Anti-infectives

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - New Jersey-headquartered pharma giant Merck and Daiichi Sankyo-controlled Ranbaxy have mutually agreed to terminate their five-year discovery research collaboration signed in May 2008. The two allies were to discover and engage in clinical development of new products in the field of anti-infectives, mainly anti-fungal and anti-bacterial drug candidates

You may also be interested in...



Ranbaxy Of India, Merck Of U.S. End Drug-Discovery Agreement

India's Ranbaxy Laboratories and U.S.-based Merck have ended a collaboration aimed at discovering and developing new drugs, as reported in PharmAsia News, Dec. 15

Ranbaxy Of India, Merck Of U.S. End Drug-Discovery Agreement

India's Ranbaxy Laboratories and U.S.-based Merck have ended a collaboration aimed at discovering and developing new drugs, as reported in PharmAsia News, Dec. 15

Ranbaxy's Discovery Unit To Move Into Daiichi Sankyo's Global R&D Structure To Create New Drugs Faster

MUMBAI - Keeping with the "hybrid business model" that it envisioned in taking over India's largest drug maker Ranbaxy in June 2008, Daiichi Sankyo has announced that the New Drug Discovery Research unit of the Indian firm will be transferred to its global R&D structure. The transaction has been approved by India's Department of Scientific and Industrial Research

Related Content

UsernamePublicRestriction

Register

SC073809

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel